2m 2m 2m 2m 2m 2m 2m
TG Therap (TGTX)
NASDAQ
$53.95-$0.45 (-0.83%)
Price as of Jun 23, 2026 6:36 PM EDT- $8.3BMarket Cap
- 48.80%1-Year Change
- BiotechnologyIndustry
TG Therap (TGTX)
$53.95-$0.45 (-0.83%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 606.9M +84.47% | 329.0M +40.80% | 233.7M +8,290.02% | 2.8M -58.36% | |
Cost of Revenue | 100.7M +161.69% | 38.5M +172.35% | 14.1M N/A | N/A N/A | |
Gross Profit | 506.2M +74.25% | 290.5M +32.34% | 219.5M +7,782.62% | 2.8M -58.36% | |
Sales and Marketing Expense | 232.0M +50.38% | 154.3M +25.75% | 122.7M +75.28% | 70.0M -45.35% | |
Research and Development Expense | -160.2M +69.92% | -94.3M +23.75% | -76.2M -39.22% | -125.4M -43.68% | |
Depreciation and Amortization Expense | 59,000 -13.24% | 68,000 -67.77% | 211,000 -0.47% | 212,000 0.00% | |
Total Operating Expenses | 493.0M +71.72% | 287.1M +34.76% | 213.0M +8.90% | 195.6M -44.34% | |
Operating Profit | 123.3M +194.13% | 41.9M +103.21% | 20.6M +110.70% | -192.8M -44.07% | |
Interest Income | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | -12.6M +23.79% | -10.2M +80.76% | |
Interest Income and Expense and Net | 0 N/A | 0 +100.00% | -12.6M +23.79% | -10.2M +80.76% | |
Total Nonoperating Income and Expense | -15.9M -2.45% | -16.3M +115.76% | -7.6M +37.75% | -5.5M +65.00% | |
Income before Taxes | 107.4M +319.59% | 25.6M +95.94% | 13.1M +106.77% | -192.8M -44.07% | |
Income Taxes | -339.8M -15,468.11% | 2.2M +466.92% | 390,000 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | 447.2M +1,812.41% | 23.4M +84.52% | 12.7M +106.39% | -198.3M -43.02% | |
Net Income from Continuing Operations Applicable to Common | 107.4M +319.59% | 25.6M +95.94% | 13.1M +106.59% | -198.3M -43.02% | |
Basic EPS and Net Income | 3.10 +1,837.50% | 0.16 +77.78% | 0.09 +106.16% | -1.46 -44.49% | |
Diluted EPS and Net Income | 2.77 +1,746.67% | 0.15 +66.67% | 0.09 +106.16% | -1.46 -44.49% | |
Basic Weighted Average Shares | 144.3M -0.69% | 145.3M +2.37% | 142.0M +4.83% | 135.4M +2.41% | |
Diluted Weighted Average Shares | 161.4M +0.67% | 160.3M +7.96% | 148.5M +9.67% | 135.4M +2.41% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 79.1M -56.00% | 179.9M +93.57% | 92.9M -9.16% | 102.3M -65.77% | |
Short-Term Investments | 62.8M -52.08% | 131.1M +5.24% | 124.6M +109.81% | 59.4M +273.99% | |
Cash and Cash Equivalents and Short-Term Investments | 142.0M -54.35% | 311.0M +42.98% | 217.5M +34.53% | 161.7M -48.64% | |
Total Current Assets | 630.8M +11.37% | 566.4M +78.13% | 317.9M +88.94% | 168.3M -49.16% | |
Accumulated Depreciation | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Property and Plant and Equipment and Net | N/A N/A | N/A N/A | 95,000 -69.06% | 307,000 -48.83% | |
Total Long-Term Assets | 2.0M -1.45% | 2.1M +2,083.16% | 95,000 -69.06% | 307,000 -48.83% | |
Total Assets | 1.1B +84.05% | 577.7M +75.28% | 329.6M +70.27% | 193.6M -49.01% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 0 -100.00% | 600,000 -92.86% | 8.4M N/A | 0 -100.00% | |
Total Current Liabilities | 153.8M +69.57% | 90.7M +68.80% | 53.7M +0.98% | 53.2M -18.63% | |
Total Long-Term Debt | 736.9M +201.49% | 244.4M +144.14% | 100.1M +40.74% | 71.1M +6.51% | |
Total Long-Term Liabilities | 269.6M +1.86% | 264.6M +129.40% | 115.4M +41.06% | 81.8M +6.09% | |
Total Liabilities | 415.2M +16.86% | 355.3M +110.15% | 169.1M +25.26% | 135.0M -5.26% | |
Retained Earnings | -1.1B -29.24% | -1.5B +0.98% | -1.5B -0.83% | -1.5B +14.93% | |
Total Stockholders Equity | 648.0M +191.42% | 222.4M +38.54% | 160.5M +173.95% | 58.6M -75.30% | |
Total Shares Outstanding | 155.3M -0.34% | 155.8M +2.91% | 151.4M +3.44% | 146.4M +2.19% | |
Cash Flow | |||||
Cash from Operating Activities | -24.8M -38.86% | -40.5M +28.98% | -31.4M -82.17% | -176.2M -40.41% | |
Capital Expenditures | 214,000 +375.56% | 45,000 N/A | 0 -100.00% | 14,000 -96.51% | |
Cash from Investing Activities | 13.8M +1,431.95% | -1.0M -97.95% | -50.7M +153.09% | -20.0M +5,928.01% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -89.7M -169.81% | 128.5M +76.78% | 72.7M +18,694.63% | -391,000 -100.94% | |
Financials Ratio | |||||
Gross Margin | 83.41% -5.55% | 88.30% -6.01% | 93.95% N/A | N/A N/A | |
Operating Margin | 20.32% +59.44% | 12.74% +44.32% | 8.83% +100.13% | -6,924.20% +34.34% | |
Return on Assets | 54.50% +957.38% | 5.15% +6.40% | 4.84% +107.00% | -69.20% -0.08% | |
Return on Equity | 102.75% +741.24% | 12.21% +5.59% | 11.57% +108.62% | -134.13% +45.75% | |
Revenue Growth | 84.47% +107.03% | 40.80% -99.51% | 8,290.02% +14,303.87% | -58.36% -101.36% | |
Current Ratio | 4.10 -34.32% | 6.25 +5.53% | 5.92 +87.12% | 3.16 -37.51% | |
Cash Ratio | 0.51 -74.05% | 1.98 +14.68% | 1.73 -10.04% | 1.92 -57.93% | |
Debt-to-Equity Ratio | 1.14 +3.20% | 1.10 +62.98% | 0.68 -44.32% | 1.21 +324.99% | |
Debt-to-Assets Ratio | 0.69 +63.39% | 0.42 +28.82% | 0.33 -10.39% | 0.37 +105.88% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow